en
Scientific article
Open access
English

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes

Published inBritish Journal of Cancer, vol. 120, no. 9, p. 913-921
Publication date2019
Abstract

We explored, within the EORTC10994 study, the outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry (IHC) as androgen-receptor (AR) positive, oestrogen (ER) and progesterone (PR) negative. We also assessed the concordance between IHC and gene expression arrays (GEA) in the identification of MA cancers.

Citation (ISO format)
BONNEFOI, Hervé et al. Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. In: British Journal of Cancer, 2019, vol. 120, n° 9, p. 913–921. doi: 10.1038/s41416-019-0420-y
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal0007-0920
303views
147downloads

Technical informations

Creation04/04/2019 1:57:00 PM
First validation04/04/2019 1:57:00 PM
Update time03/15/2023 4:26:45 PM
Status update03/15/2023 4:26:43 PM
Last indexation02/12/2024 11:40:33 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack